Our Company

Inflection Biosciences is developing small molecule therapeutics for the treatment of cancer. The pipeline includes first-in-class IBL-202, a dual PIM and PI3K inhibitor in development for B-cell malignancies. The IBL-100s comprises selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, being developed by AUM Biosciences.